I mean... we know that, right? We live in it. The individuals reading these words right now have spent years, even decades, fighting the "health care" system to make it do what it is being paid trillions of dollars to do, which is to make people healthier. Even having to fight just to get permission to make their own individual family members healthier at their own expense. To us the claims from government and industry officials care about the health of Americans and the advancement of science to actually improve health outcomes for Americans is laughable.
But rarely do we get to see the industry saying that profits are more important than patient health out loud and in public where everyone can hear them. And even when they do, rarely does the press cover it. But they all did this week.
I mean, usually health care corporations and their financial partners are smart enough to hide their cynical money grubbing, but one set of analyists apparently forgot to do so, not only pointing out that cures hurt profits, but LAMENTING THAT ONE NEW TREATMENT HAD DONE SUCH A GOOD JOB AT CURING A COMMUNICABLE DISEASE, THAT THERE WOULD NOT BE ENOUGH CARRIERS OF THE DISEASE TO KEEP SPREADING IT AROUND TO OTHERS, IMPAIRING THEIR ABILITY TO CONTINUE TO MAKE MONEY OFF THE CURE! After which they make the observation that well... if you do gotta cure stuff make it cancer or something that can come back, just dont wipe the disease completely out of the population. Because you need to stay in business.
Behold with your own eyes:
Tae Kim | @firstadopterPublished 3:15 PM ET Wed, 11 April 2018 Updated 7:20 PM ET Wed, 11 April 2018
Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering "gene therapy" treatment: cures could be bad for business in the long run.
"Is curing patients a sustainable business model?" analysts ask in an April 10 report entitled "The Genome Revolution."
"The potential to deliver 'one shot cures' is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies," analyst Salveen Richter wrote in the note to clients Tuesday. "While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow."
Richter cited Gilead Sciences' treatments for hepatitis C, which achieved cure rates of more than 90 percent. The company's U.S. sales for these hepatitis C treatments peaked at $12.5 billion in 2015, but have been falling ever since. Goldman estimates the U.S. sales for these treatments will be less than $4 billion this year, according to a table in the report.
"GILD is a case in point, where the success of its hepatitis C franchise has gradually exhausted the available pool of treatable patients," the analyst wrote. "In the case of infectious diseases such as hepatitis C, curing existing patients also decreases the number of carriers able to transmit the virus to new patients, thus the incident pool also declines … Where an incident pool remains stable (eg, in cancer) the potential for a cure poses less risk to the sustainability of a franchise."
The analyst didn't immediately respond to a request for comment.
The report suggested three potential solutions for biotech firms:
"Solution 1: Address large markets: Hemophilia is a $9-10bn WW market (hemophilia A, B), growing at ~6-7% annually."
"Solution 2: Address disorders with high incidence: Spinal muscular atrophy (SMA) affects the cells (neurons) in the spinal cord, impacting the ability to walk, eat, or breathe."
"Solution 3: Constant innovation and portfolio expansion: There are hundreds of inherited retinal diseases (genetics forms of blindness) … Pace of innovation will also play a role as future programs can offset the declining revenue trajectory of prior assets."
I know right? I can't believe they said this out in the open either.
But the report only confirms the assertions made by the notable bioethicist Christ Rock for years, "Ain't no money in the cure, the money's in the medicine...that's how a drug dealer makes his money, on the comeback."
So when you walk into a pharmacy to fill a perscription, be honest with yourself about who you are doing business with, and what their real motives are about healing what ails you.
“When people show you who they are, believe them the first time.” - Maya Angelou